

iScience, Volume 27

Supplemental information

Pseudouridine synthase 1 regulates

erythropoiesis via transfer RNAs

pseudouridylation and cytoplasmic translation

Deyang Shi, Bichen Wang, Haoyuan Li, Yu Lian, Qiuyi Ma, Tong Liu, Mutian Cao, Yuanwu Ma, Lei Shi, Weiping Yuan, Jun Shi, and Yajing Chu

Supplementary material

This supplementary material includes 9 supplementary figures




Figure S1 Mutation in *Pus1* cause anemia without ring sideroblasts, related to Figure 1.

(A) Co-localization of PUS1 with nucleus and mitochondria in mouse bone marrow cells by immunofluorescence (DAPI in blue; Mitotracker in green; PUS1 in red; Scale bars, 10 μ m). (B) Complete blood routine of R110W and WT control mice (n=4). (C) The frequencies of CD3⁺ T lymphocytes (T cells), B220⁺ B lymphocytes (B cells), Mac1⁺Gr1⁺ and Mac1⁺Gr1⁻ myeloid cells in peripheral blood (n=14 for WT; n=11 for R110W). (D) Serum iron concentration in R110W and WT mice (n=5 for WT; n=3 for R110W). (E) Perl's staining of BM erythroblasts in R110W and WT mice (Scale bars, 10 μ m). Data are represented as Mean \pm SEM; * P < 0.05, ** P < 0.01, *** P < 0.001.




Figure S2 R110W mice impedes erythropoiesis in BM and spleen, related to Figure 2.

(A) The absolute cell number of erythroblasts in BM at different stages (n=4). (B) The absolute cell number of erythroblasts in spleen at different stages (n=4 for WT; n=3 for R110W). (C) MFI peak of CD71 in BM erythroblasts of the two groups. (D) MFI values of CD71 in BM erythroblasts of the two groups (n=4). (E) MFI peak of C11-BODIPY (581/591) (Lipid Peroxidation Sensor) in BM erythroblasts (n=3); Negative is the sample without sensor. (F) MFI values of C11-BODIPY (581/591) in BM erythroblasts (left, n=3). MFI values of C11-BODIPY (581/591) in spleen erythroblasts (right, n=3). Data are represented as Mean \pm SEM; * P < 0.05, ** P < 0.01, *** P < 0.001.




Figure S3 Effects of PUS1 on hematopoietic stem and progenitor cells, related to Figure 2.

(A) Flow cytometric gating strategy of LSK⁺ and LSK⁻ cells in BM. (B) The proportion of LSK⁺ and LSK⁻ cells in BM of R110W and WT control (n=22 for WT; n=18 for R110W). (C) Flow cytometric gating strategy of LT-HSC, ST-HSC and MPP cells in BM. (D) The proportion of long-term hematopoietic stem cells (LT-HSC), short-term hematopoietic stem cells (ST-HSC) and multipotent progenitor cells (MPP) cells in BM of R110W and control mice (n=18 for WT; n=9 for R110W). (E) Flow cytometric gating strategy of MEP, CMP and GMP cells in BM. (F) The proportion of megakaryocyte-erythroid progenitor cells (MEP), common-myeloid progenitor (CMP) and granulocyte-macrophage progenitor (GMP) cells in BM of R110W and control mice (n=22 for WT; n=18 for R110W). (G, I) Morphological characteristics of BFU-E (G, Scale bars, 100 μ m) and CFU-E (I, Scale bars, 20 μ m) differentiated from BM cells of R110W and control mice; Scale bars, 10 μ m. (H, J) The colony counts of BFU-E (H) or CFU-E (J) differentiated from 4×10^4 BM cells (n=4). Data are represented as Mean \pm SEM; * P < 0.05, ** P < 0.01, *** P < 0.001.




Figure S4 Analysis of donor derived cells in transplantation assay, related to Figure 2 and Figure 3.

(A) The proportion of GFP⁺ erythrocytes and platelets in peripheral blood of actin-GFP mice. (B) Flow cytometric gating strategy to detect GFP⁻ chimerism of platelets and erythrocytes in peripheral blood (PB). (C) Proportion of each lineage in donor derived BM cells (n=3 for WT; n=4 for R110W). (D) Flow cytometric gating strategy of donor derived GFP myeloid cells, T cells and B cells (left) and the frequency of donor derived GFP⁻ cells (right, n=4). (E) MFI values of MitoSox in BM erythroblasts (n=20 for WT; n=16 for R110W). (F) MFI values of TMRE in BM erythroblasts (n=24 for WT; n=20 for R110W). (G) MFI values of Mitotracker in BM erythroblasts (n=22 for WT; n=17 for R110W). Data are represented as Mean ± SEM; * P < 0.05, ** P < 0.01, *** P < 0.001.




Figure S5 Changes in mitochondrial respiratory chain-related proteins caused by mutation in *Pus1*, related to Figure 4.

(A) Mitochondrial genome-encoded genes ranked by changed mitochondrial tRNAs (left), down-regulated mt-tRNA^{lle} (GAT) (middle) and up-regulated mt-tRNA^{Tyr} (GTA) (right) corresponding codon frequencies. (B) Expression of mitochondrial OXPHOS protein level in BM Ter119⁺ erythroblasts (left) and Ter119⁻ non-erythroblasts (right) by Western blotting; mt-CYTb (complex III subunit), ND3 (complex I subunit), mt-CO1 (complex IV subunit), mt-CO2 (complex IV subunit). The relative density was indicated.




Figure S6. PUS1 mutation on translation may not be attributed to its effect on rRNA maturation of ribosome biogenesis, related to Figure 5.

(A) RNA from fractions 1 to 6 was extracted. The expression levels of mature and intermediate products of rRNA in samples tubes 1 to 6. (B) The experimental strategy of BM erythroblasts between two groups. (C) Volcano plot of differential TE genes between R110W and control BM erythroblasts (Fold Change > 2, $p < 0.05$, $n=3$). Blue, down-regulated genes; Red, up-regulated genes. TE for each transcript was calculated by dividing normalized ribosome-protected fragment reads (as assessed by Ribo-seq) by the normalized RNA-seq reads in the form of RPKM. Data are represented as Mean \pm SEM; * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$.




Figure S7 OPP incorporation in LSK⁺ cells and Ter119⁺ erythroblasts, related to Figure 5. (A) MFI values of OPP in BM LSK⁺ cells and Ter119⁺ erythroblasts (n=3). (B) Flow cytometric gating strategy of erythroblasts in BM by CD71 and Ter119 staining. EryA / B / C are gated in BM Ter119⁺ erythroblasts. EryA: basophilic erythroblasts; EryB: polychromatophilic erythroblast; EryC: orthochromatic erythroblasts. Data are represented as Mean ± SEM; * P < 0.05, ** P < 0.01, *** P < 0.001.




Figure S8 Flow cytometric analysis of *in vitro* erythroid differentiation, related to **Figure 6**.

(A) Flow cytometric analysis strategy of differentiated erythroblasts of *in vitro* erythroid differentiation. (B) Flow cytometric analysis of inhibitors on erythropoiesis *in vitro* at 6 days after differentiation. Inhibitors and their concentration are listed in the panels.

